13D Filing: Delphi Ventures VIII LP and Karyopharm Therapeutics Inc. (KPTI)

Page 6 of 12

Page 6 of 12 – SEC Filing

CUSIP NO.   48576U106 13D Page
6 of 12
1 NAME OF REPORTING PERSON               David L. Douglass (“Douglass”)
2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)   ¨   (b)   x

3 SEC USE ONLY
4 CITIZENSHIP
OR PLACE OF ORGANIZATION
U.S. Citizen

 

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY EACH

REPORTING

PERSON

WITH

5 SOLE VOTING POWER
0 shares.
6 SHARED VOTING POWER
2,263,006 shares, of which 2,241,123 shares are directly owned by Delphi VIII and 21,883 shares are directly owned by DBI VIII.  Douglass is a managing member of DMP VIII, the general partner of each of Delphi VIII and DBI VIII, and may be deemed to have shared power to vote these shares.
7 SOLE DISPOSITIVE POWER
0 shares.
8 SHARED DISPOSITIVE POWER
2,263,006 shares, of which 2,241,123 shares are directly owned by Delphi VIII and 21,883 shares are directly owned by DBI VIII.  Douglass is a managing member of DMP VIII, the general partner of each of Delphi VIII and DBI VIII, and may be deemed to have shared power to dispose of these shares.

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON

2,263,006

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES*

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW
9

4.8%

12

TYPE OF REPORTING PERSON*

IN

Follow Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Page 6 of 12